Use of calibrated automated thrombinography ± thrombomodulin to recognise the prothrombotic phenotype

Summary

There is currently no validated method to detect a prothrombotic phenotype. The question remains, can tissue factor (TF) induced thrombin generation (TG), as measured with the calibrated automated thrombinography (CAT) technique, according to Hemker et al., recognise a prothrombotic state either as such, or when the activated proteinC (APC)-system is boosted with thrombomodulin (TM)? We determined the normal range of CAT-TG ± TM in a group of 71 healthy blood donors, in 11 healthy women using oral contraceptives (OC), and in 89 patients with a history of venous thromboembolism (VTE), divided into a group of 50 in whicha prothrombotic risk factor could be found (VTEprf+) and 39 others (VTEprf-). The endogenous thrombin potential (ETP) in the OC, VTEprf+ and VTEprf-group was significantly higher than for the controls. In the presence of TM, the differences were significantly higher than in its absence. The VTEprf+ group had a higher ETP, ± TM than the VTEprf group. In conclusion,TG, measured with the CAT technique in the presence of TM is capable of detecting the prothrombotic phenotype with a high sensitivity of 0.93 (95% confidence limits 0.82–0.99).

Keywords

Thrombin generation - thrombomodulin - hypercoagulability - calibrated automated thrombogram,venous thromboembolism

• References

• 1 Lane DA, Mannucci PM, Bauer KA. et al. Inherited thrombophilia. Part I. Thromb Haemost 1996; 76: 651-2.
• 2 Laffan M, Tuddenham E. Science, medicine and the future: assessing thrombotic risk. Br Med J 1998; 317: 520-3.
• 3 Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86: 395-403.
• 4 Zoller B, Berntsdotter A, Garcia P. et al. Resistance to activated protein C as an additional risk factor for thrombosis in protein C deficient families. Blood 1995; 85: 3518-23.
• 5 Baglin T. The measurement and application of thrombin generation. Brit J Haematol 2005; 130: 653-61.
• 6 Mannucci PM. The measurement of multifactorial thrombophilia. Thromb Haemost 2002; 88: 1-2.
• 7 Hemker HC, Giesen P, Al Dieri R. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper-and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
• 8 Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747-51.
• 9 Curvers J, Thomassen MCLG, Rimmer J. et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance. Thromb Haemost 2002; 88: 5-11.
• 10 Chantarangkul V, Clerici M, Bressi C. et al. TG assessed as endogenous thrombin potential in patients with hyper-or hypo-coagulability. Haematologica 2003; 88: 547-54.
• 11 Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay process. Thromb Haemost 1986; 56: 9-17.
• 12 De Visser MCH, Van Hylckama AVlieg, Tans G. et al. Determinants of the aPTT-and ETP-based APC sensitivity tests. J Thromb Haemost 2005; 03: 1488-94.
• 13 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated TG measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
• 14 Duchemin J, Pittet JL, Tartary M. et al. A new assay based on TG inhibition to detect both protein-C and protein S deficiencies in plasma. Thromb Haemost 1994; 71: 331-8.
• 15 Koster T, Rosendaal FR, de Ronde H. et al. Venous thrombosis due to poor anticoagulant response to activated proteinC : Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
• 16 Exner T. Diagnostic methodologies for circulating anticoagulants. Thromb Haemost 1995; 74: 338-44.
• 17 Ripoll L, Paulin D, Thomas S. et al. Multiplex PCRmediated site-directed mutagenesis for one step determination of factor V Leiden and G20210A transition of the prothrombin gene. Thromb Haemost 1997; 78: 960-1.
• 18 Hope MJ, Bally MB, Webb G. et al. Production of large unilamellar vesicles by rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985; 812: 55-65.
• 19 Hedegaard E, Jensen B. Nano-scale densitometric quantitation of phospholipids. J Chromatogr 1981; 225: 450-4.
• 20 Regnault V, Beguin S, Lecompte T. Calibrated automated thrombin generation in frozen-thawed plateletrich plasma to detect hypercoagulability. Pathophysiol Haemost Thromb 2003; 33: 23-9.
• 21 Hemker HC, Al Dieri R, Beguin S. TG assays: accruing clinical relevance. Curr Opin Hematol 2004; 11: 170-5.
• 22 Regnault V, Hemker HC, Wahl D. et al. Phenotyping the haemostatic system by thrombography-potential for the estimation of thrombotic risk. Thromb Res 2004; 114: 539-45.
• 23 Rosing J, Tans G, Nicolaes AF. et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second and third generation oral contraceptives. Brit J Haematol 1997; 97: 233-8.
• 24 Kyrle PA, Mannhalter C, Beguin S. et al. Clinical studies and TG in patients homozygous and heterozygous for the G20210A mutation in prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.
• 25 Wielders S, Mukherjee M, Michiels J. et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper-and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
• 26 Butenas S, van’t Veer C, Mann KG. “Normal” thrombin generation. Blood 1999; 94: 2169-78.
• 27 Suehisa E, Toku M, Kawasaki T. et al. Measurement of a newly developed thrombomodulin addition activated partial thromboplastin time assay in patients with deep venous thrombosis. Haemostasis 2001; 31: 26-31.
• 28 Andresen MS, Abildgaard U. Coagulation inhibitor potential: a study of assay variables. Thromb Res 2005; 115: 519-26.
• 29 Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004-8.
• 30 Rosing J, Middeldorp S, Curvers J. et al. Low-dose oral contraceptives and acquired resistance to activated protein C:a randomised cross-over study. Lancet 1999; 354: 2036-40.
• 31 Legnani C, Cosmi B, Cini M. et al. High plasma levels of FVIII and the risk of recurrence of venous thromboembolism. Brit J Haematol 2004; 124: 504-10.
• 32 Keularts IM, Hamulyak K, Hemker HC. et al. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. Thromb Haemost 2000; 84: 638-42.
• 33 Tripodi A, Chantarangkul V, Mannucci PM. Hyperprothrombinemia may result in acquired activated protein C resistance. Blood 2000; 96: 3295-6.
• 34 Smirnov MD, Safa O, Esmon NL. et al. Inhibition of activated protein C anticoagulant activity by prothrombin. Blood 1999; 94: 3839-46.
• 35 De Stefano V. Inherited thrombophilia and life-time risk of venous thrombo-embolism: is the burden reducible?. J Thromb Haemost 2004; 02: 1522-25.
• 36 Hezard N, Bouaziz-Borgi L, Remy MG. et al. Utility of thrombin generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency. Clin Chem 2006; 52: 665-70.